More study data available!
Data has been uploaded for 3 Ph I/II clinical trials, 7 NHP studies, and 3 other animal studies including:
- Clinical trials
- Pantaleo Ph I/II study (CAVD 256/EV03/ANRSVAC20) comparing DNA-C/NYVAC prime/boost regimens
- Schlesinger Ph I studies (CAVD 264/DCVAX and CAVD 579/DCVAX boost) comparing increasing doses of the monoclonal antibody vaccine, DEC-205-p24, followed by boost immunizations with MVA-CMDR
- NHP studies
- Pantaleo NHP study evaluating different prime/boost regimens using combinations of NYVAC, protein, and adjuvant products (CAVD 408/AUP518). With the upload of data for CAVD 408, NAB, BAMA, and ICS data is now available for all 6 of the Pantaleo NHP studies comparing NYVAC regimens
- Gallo NHP studies evaluating vaccine regimens using prophylactic neutralizing antibodies (CAVD 422) and comparing different adjuvants combined with the rhFLSC protein (CAVD 506)
- Haynes NHP study comparing different doses of an MPER peptide liposome (CAVD 625)
- McElrath/Pulendran NHP study comparing different adjuvants in combination with subunit proteins (CAVD 355)
- Letvin NHP study comparing different ALVAC and AIDSVAX B/E prime/boost regimens (CAVD 364)
- Animal studies
- Lu study evaluating the immunogenicity of novel glycan modified Env protein in rabbits
- Hu study evaluating vaccinia vector and heterologous N7 Env prime/boost regimens in rabbits
- Frank study comparing regimens using alum-adjuvanted, stabilized 1086C and/or JRFL and a complement activator
Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies.
Data was uploaded for the following studies:
|
Name & Description |
Data Added |
Type |
PI |
Strategy |
|
CAVD 256 (EV03/ANRSVAC20) is Phase I/II study to compare the immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost |
BAMA |
Phase I/II |
Pantaleo |
Combo: DNA & vector vaccines |
|
CAVD 264 (DCVAX) is a Ph I clinical trial comparing increasing dose of the monoclonal antibody vaccine, DEC-205-p24 |
BAMA, ICS |
Phase I |
Schlesinger |
Prophylactic neutralizing Ab |
|
CAVD 355 (CAVIMC-045) is a non-human primate study of protein and adjuvant regimens |
NAB |
Pre-Clinical NHP |
McElrath |
Protein and peptide vaccines |
|
CAVD 364 is a non-human primate study of ALVAC-HIV (vCP1521) and AIDSVAX B/E prime/boost regimens |
NAB |
Pre-Clinical NHP |
Letvin |
Combo: Protein & vector vaccines |
|
CAVD 408 (AUP 518) is a non-human primate study comparing NYVAC/protein-adjuvant prime/boost regimens |
BAMA, NAB, ICS |
Pre-Clinical NHP |
Pantaleo |
Combo: Protein & vector vaccines |
|
CAVD 422 is a non-human primate challenge study comparing passive immunization regimens using broadly neutralizing monoclonal antibodies |
NAB |
Pre-Clinical NHP |
Gallo |
Combo: Protein & vector vaccines |
|
CAVD 436 is preclinical rabbit study evaluating the immunogenicity of novel glycan modified Env protein by epitope mapping rabbit sera induced with glycan modified Envs produced in Pichia pastoris |
NAB |
Pre-Clinical Non-NHP |
Lu |
Protein and peptide vaccines |
|
CAVD 449 is a preclinical rabbit study to evaluate the antibody responses following vaccinia vector and heterologous N7 Env prime/boost regimens |
NAB |
Pre-Clinical Non-NHP |
Hu |
Combo: Protein & vector vaccines |
|
CAVD 468 is a preclinical mouse study to compare regimens using stabilized 1086C and/or JRFL and a Complement Activator with and without Alum |
NAB |
Pre-Clinical Non-NHP |
Frank |
Protein and peptide vaccines |
|
CAVD 506 is a non-human primate study of different adjuvants in combination with the rhFLSC immunogen |
NAB |
Pre-Clinical NHP |
Gallo |
Protein and peptide vaccines |
|
CAVD 579 (SSC-0803 or TP 22) is a Ph I trial comparing boost immunizations with MVA-CMDR in participants previously immunized with the monoclonal antibody, DCVax-001, in CAVD 264 (DC Vax) |
BAMA, ICS |
Phase I |
Schlesinger |
Prophylactic neutralizing Ab |
|
CAVD 625 is a non-human primate study comparing different doses of an MPER peptide liposome regimen |
NAB |
Pre-Clinical NHP |
Haynes |
Protein and peptide vaccines |